Article

Cohort monitoring of 29 Adverse Events of Special Interest prior to and after COVID-19 vaccination in four large European electronic healthcare data sources

2022-08-20

Abstract excerpt

<h4>Setting</h4> Primary and/or secondary health care data from four European countries: Italy, the Netherlands, the United Kingdom, Spain <h4>Participants</h4> Individuals with complete data for the year preceding enrollment or those born at the start of observation time. The cohort comprised 25,720,158 subjects. <h4>Interventions</h4> First and second dose of Pfizer, AstraZeneca, Moderna, or Janssen COVID-19 vac...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: dafe9b39-ea6a-51ec-b61e-2277ef2503bb
DOI: 10.1101/2022.08.17.22278894

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cohort monitoring of 29 Adverse Events of Special Interest prior to and after COVID-19 vaccination in four large European electronic healthcare data sourcesDOI 10.1101/2022.08.17.22278894Read

Background Rates of 41 Adverse Events of Special Interest for COVID-19 Vaccines in 10 European Healthcare Databases - An ACCESS Cohort StudySemantic proximity Read

Background Rates of 41 Adverse Events of Special Interest for COVID-19 Vaccines in 10 European Healthcare Databases - an ACCESS Cohort StudySemantic proximity Read

Adverse events of special interest for COVID-19 vaccines - background incidences vary by sex, age and time period and are affected by the pandemicSemantic proximity Read

A 6-week time period may not be sufficient to identify potential adverse events following COVID-19 vaccinationSemantic proximity Read

Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillanceSemantic proximity Read

Impact of vaccination on the association of COVID-19 with arterial and venous thrombotic diseases: an OpenSAFELY cohort study using linked electronic health recordsSemantic proximity Read

Exploring Temporal and Spatial Characteristics of Serious Adverse Event Reports Following COVID-19 Bivalent VaccinesSemantic proximity Read

Incidence and management of the main adverse effects reported after COVID-19 vaccinationSemantic proximity Read

Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 25.4 million people in six European countriesSemantic proximity Read

Serious adverse events reported from the COVID-19 vaccines: A descriptive study based on WHO databaseSemantic proximity Read

Risk of Neurologic or Immune-Mediated Adverse Events After COVID-19 Diagnosis in the United StatesSemantic proximity Read

An objective systematic comparison of the most common adverse events of COVID-19 vaccinesSemantic proximity Read